News

HealthDay on MSN4h
New Framework Reclassifies Nearly 20 Percent of People as Having Obesity
The European Association for the Study of Obesity (EASO) framework may offer a more sensitive measure of obesity than ...
Rhythm Pharma Shares Gain on Positive Results From Recent Trial of Obesity Treatment
Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...
Stocktwits on MSN9h
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and ...
Being on Mounjaro is no joke – I had the most embarrassing side effect & ended up on a corner shop loo…but it gets worse
A MOUNJARO user has candidly opened up on what happened after she used fat jabs for just four weeks. Despite being “really happy” with losing two to three lbs a week on the injections, Megan ...
MetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...
Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo ...
Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...